95 related articles for article (PubMed ID: 12738748)
1. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
2. Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells.
Bacac M; Vadori M; Sava G; Pacor S
Cancer Immunol Immunother; 2004 Dec; 53(12):1101-10. PubMed ID: 15221285
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of oversulfated fucoidan on invasion through reconstituted basement membrane by murine Lewis lung carcinoma.
Soeda S; Ishida S; Shimeno H; Nagamatsu A
Jpn J Cancer Res; 1994 Nov; 85(11):1144-50. PubMed ID: 7829400
[TBL] [Abstract][Full Text] [Related]
4. Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies.
Barbera-Guillem E; May KF; Nyhus JK; Nelson MB
Neoplasia; 1999 Nov; 1(5):453-60. PubMed ID: 10933061
[TBL] [Abstract][Full Text] [Related]
5. [Establishment and evaluation of pre-metastatic niche mouse model labelled with luciferase in lewis lung cancer cells].
Ming H; Shen M; Chen Y; Li Y; Yang L; Liang Q; Liu Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Dec; 39(12):1083-1088. PubMed ID: 38140867
[TBL] [Abstract][Full Text] [Related]
6. Localization of Cancer Cells for Subsequent Robust Photodynamic Therapy by ROS Responsive Polymeric Nanoparticles With Anti-Metastasis Complexes NAMI-A.
Zhang H; Cui M; Tang D; Wang B; Liang G; Xu C; Xiao H
Adv Mater; 2024 Apr; 36(14):e2310298. PubMed ID: 38145801
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.
Leijen S; Burgers SA; Baas P; Pluim D; Tibben M; van Werkhoven E; Alessio E; Sava G; Beijnen JH; Schellens JH
Invest New Drugs; 2015 Feb; 33(1):201-14. PubMed ID: 25344453
[TBL] [Abstract][Full Text] [Related]
8. The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae.
Stevens SK; Strehle AP; Miller RL; Gammons SH; Hoffman KJ; McCarty JT; Miller ME; Stultz LK; Hanson PK
Mol Pharmacol; 2013 Jan; 83(1):225-34. PubMed ID: 23090979
[TBL] [Abstract][Full Text] [Related]
9. Ruthenium complexes as anticancer agents.
Kostova I
Curr Med Chem; 2006; 13(9):1085-107. PubMed ID: 16611086
[TBL] [Abstract][Full Text] [Related]
10. From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).
Hartinger CG; Zorbas-Seifried S; Jakupec MA; Kynast B; Zorbas H; Keppler BK
J Inorg Biochem; 2006 May; 100(5-6):891-904. PubMed ID: 16603249
[TBL] [Abstract][Full Text] [Related]
11. Ruthenium antimetastatic agents.
Alessio E; Mestroni G; Bergamo A; Sava G
Curr Top Med Chem; 2004; 4(15):1525-35. PubMed ID: 15579094
[TBL] [Abstract][Full Text] [Related]
12. Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.
Sava G; Frausin F; Cocchietto M; Vita F; Podda E; Spessotto P; Furlani A; Scarcia V; Zabucchi G
Eur J Cancer; 2004 Jun; 40(9):1383-96. PubMed ID: 15177498
[TBL] [Abstract][Full Text] [Related]
13. KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.
Hartinger CG; Jakupec MA; Zorbas-Seifried S; Groessl M; Egger A; Berger W; Zorbas H; Dyson PJ; Keppler BK
Chem Biodivers; 2008 Oct; 5(10):2140-2155. PubMed ID: 18972504
[TBL] [Abstract][Full Text] [Related]
14. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J
J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322
[TBL] [Abstract][Full Text] [Related]
15. Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.
Bergamo A; Messori L; Piccioli F; Cocchietto M; Sava G
Invest New Drugs; 2003 Nov; 21(4):401-11. PubMed ID: 14586207
[TBL] [Abstract][Full Text] [Related]
16. Comparison of KP1019 and NAMI-A in tumour-mimetic environments.
Gransbury GK; Kappen P; Glover CJ; Hughes JN; Levina A; Lay PA; Musgrave IF; Harris HH
Metallomics; 2016 Aug; 8(8):762-73. PubMed ID: 27460862
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
[TBL] [Abstract][Full Text] [Related]
18. Nanoformulation improves activity of the (pre)clinical anticancer ruthenium complex KP1019.
Heffeter P; Riabtseva A; Senkiv Y; Kowol CR; Körner W; Jungwith U; Mitina N; Keppler BK; Konstantinova T; Yanchuk I; Stoika R; Zaichenko A; Berger W
J Biomed Nanotechnol; 2014 May; 10(5):877-84. PubMed ID: 24734541
[TBL] [Abstract][Full Text] [Related]
19. Pyridine analogues of the antimetastatic Ru(III) complex NAMI-A targeting non-covalent interactions with albumin.
Webb MI; Chard RA; Al-Jobory YM; Jones MR; Wong EW; Walsby CJ
Inorg Chem; 2012 Jan; 51(2):954-66. PubMed ID: 22224431
[TBL] [Abstract][Full Text] [Related]
20. Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis ES; Emadi A
Cancer Chemother Pharmacol; 2010 May; 66(1):1-9. PubMed ID: 20213076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
